Know Cancer

forgot password

A Randomized Study to Determine Whether ArginMax Improves the Sexual Function and Quality of Life in Female Cancer Survivors

18 Years
Not Enrolling
Sexual Dysfunction, Sexuality and Reproductive Issues, Unspecified Adult Solid Tumor, Protocol Specific

Thank you

Trial Information

A Randomized Study to Determine Whether ArginMax Improves the Sexual Function and Quality of Life in Female Cancer Survivors



- Determine whether an L-arginine-based nutritional supplement (ArginMax®) improves the
quality of life and sexual function in female cancer survivors.


- Compare quality of life of patients treated with ArginMax® vs placebo.

- Compare toxicity of these regimens in these patients.

- Describe the sexual function symptom clusters (if any) in these patients.

OUTLINE: This is a randomized, double-blind, parallel-group, placebo-controlled, multicenter
study. Patients are stratified according to ECOG performance status (0 or 1 vs 2 or 3), type
of malignancy (pelvic vs nonpelvic), and ovarian functional status (yes vs no). Patients are
randomized to 1 of 2 treatment arms.

- Arm I: Patients receive an oral L-arginine-based nutritional supplement (ArginMax®)
twice daily.

- Arm II: Patients receive oral placebo twice daily. In both arms, treatment continues
for 12 weeks in the absence of unacceptable toxicity.

Sexual function, quality of life, and toxicity are assessed at baseline and every 4 weeks
for 12 weeks.

PROJECTED ACCRUAL: A total of 186 patients will be accrued for this study.

Inclusion Criteria


Any female cancer survivor who identifies herself as concerned with her sexual quality of
life and answering yes to all three of the screening questions.

- Must express interest in sexual activity

- At least 6 months following completion of all cancer therapy. Hormonal therapy and
treatment with Herceptin are allowed.

- No evidence of active cancer based on physical exam and/or radiographic images
obtained within 3 months of study.

- Absence of any mental, medical or physical disorder know to affect sexual function.

- No participation in another study with an investigational study drug or device during
the 30 days prior to start of study drug.

- Lab values must meet the following criteria at study entry: WBC ≥ 2000, Hgb ≥
10gm/dl, creatinine ≤ 1.5 x ULN, plt ≥ 100,000, T Bili ≤ 1.5

- ECOG performance status must be 0-2.

- Must be able to take oral medication

- Must be 18 years old or older

- Must be minority (non-white) female.


- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to ArginMax.

- Currently taking any blood thinner such as aspirin (one 81mg aspirin, or one baby
aspirin per day allowed), Persantine, Heparin, Lovenox, or Coumadin (low dose
Coumadin for catheter patency is allowed).

- Patients currently taking Ginkgo Biloba are not allowed on this study.

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac,
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements and/or ability for sexual function.

- Pregnant women are excluded from this study because ArginMax may be an agent with the
potential for teratogenic or abortifacient effects. Because there is an unknown but
potential risk for adverse events in nursing infants secondary to treatment of the
mother with ArginMax, breastfeeding should be discontinued if the mother is treated
with ArginMax.

- Because patients with immune deficiency are at increased risk of lethal infections
when treated with marrow-suppressive therapy, HIV-positive patients receiving
combination anti-retroviral therapy are excluded from the study because of possible
pharmacokinetic interactions with ArginMax. Appropriate studies will be undertaken in
patients receiving combination anti-retroviral therapy when indicated.

- Any planned surgery during study participation.

Type of Study:


Study Design:

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care

Outcome Measure:

Determine whether ArginMax improves the quality of life and sexual function.

Outcome Description:

Determine whether ArginMax improves the quality of life and sexual function for women cancer survivors by using the FACT-G and FSFI instruments.

Outcome Time Frame:

12 weeks

Safety Issue:


Principal Investigator

Kathryn M. Greven, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Wake Forest Cancer Center CCOP Research Base


United States: Food and Drug Administration

Study ID:

CCCWFU 97106



Start Date:

May 2007

Completion Date:

March 2010

Related Keywords:

  • Sexual Dysfunction
  • Sexuality and Reproductive Issues
  • Unspecified Adult Solid Tumor, Protocol Specific
  • sexual dysfunction
  • sexuality and reproductive issues
  • unspecified adult solid tumor, protocol specific
  • Sexual Dysfunctions, Psychological



CCOP - Upstate Carolina Spartanburg, South Carolina  29303
CCOP - Christiana Care Health Services Wilmington, Delaware  19899
CCOP - Mount Sinai Medical Center Miami Beach, Florida  33140
CCOP - North Shore University Hospital Manhasset, New York  11030
Cedar Rapids Oncology Associates Cedar Rapids, Iowa  52403
CCOP - Michigan Cancer Research Consortium Ann Arbor, Michigan  48106
CCOP - Sioux Community Cancer Consortium Sioux Falls, South Dakota  57105-1080
CCOP - Central Illinois Springfield, Illinois  62526
CCOP - Cancer Research for the Ozarks Springfield, Missouri  65807
CCOP - Columbus Columbus, Ohio  43206
CCOP - Northern Indiana CR Consortium South Bend, Indiana  46601
MBCCOP - LSU Health Sciences Center New Orleans, Louisiana  70112
CCOP - St. Louis-Cape Girardeau Saint Louis, Missouri  63141
CCOP - Beaumont Royal Oak, Michigan  48073-6769
Wake Forest University Comprehensive Cancer Center Winston-Salem, North Carolina  27157-1096
MBCCOP - Medical College of Georgia Cancer Center Augusta, Georgia  30912-3730
Feist-Weiller Cancer Center at Louisiana State University Health Sciences Shreveport, Louisiana  71130-3932
CCOP - Main Line Health Wynnewood, Pennsylvania  19096
Alamance Cancer Center at Alamance Regional Medical Center Burlington, North Carolina  27216
MBCCOP - JHS Hospital of Cook County Chicago, Illinois  60612
Hugh Chatham Memorial Hospital Elkin, North Carolina  28621
Caldwell Memorial Hospital Lenoir, North Carolina  28645
Southeastern Medical Oncology Center - Goldsboro Goldsboro, North Carolina  27534
Hematology Oncology Associates of Central New York, PC - Northeast Center East Syracuse, New York  13057-4510
CCOP - Heartland Research Consortium St. Louis, Missouri  63131